Best Practices in the Diagnosis and Treatment of Inflammatory Breast Cancer

Inflammatory breast cancer signs and symptoms mimic mastitis. Many physicians do not recognize that mastitis is common in younger, premenopausal women but uncommon in the postmenopausal population. The rarity of inflammatory breast cancer compared with the frequency of mastitis or cellulitis of the breast often results in a delay of a cancer work-up in favor of treating mastitis. This delay may affect the patient’s clinical course thus increasing the possibility of symptomatic spread of breast cancer and associated outcomes. 

The webinar will review the clinical presentation of inflammatory breast cancer, discuss the National Comprehensive Cancer Network (NCCN) guidelines for inflammatory breast cancer, and best practices for early diagnosis by primary care physicians, obstetrics/gynecology specialists, and advance practice providers.

Target Audience

  • Primary care providers
  • Obstretics/gynecology specialists
  • Advance practice providers
  • NAPBC-accredited centers
  • Patient advocacy organizations
  • Allied health professionals

Learning Objectives

  • Describe the common presentation of inflammatory breast cancer and the characteristics that differentiate it from locally advanced disease.
  • Identify best practice options for the timely diagnosis of inflammatory breast cancer.
  • Discuss the NCCN guidelines for inflammatory breast cancer and compare the differences to the guidelines for non-inflammatory invasive breast cancer.



Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Completion
  • 1.00 Self Assessment Credit
Course opens: 
Course expires: 

Disclosure Information

In accordance with the ACCME Accreditation Criteria, the American College of Surgeons must ensure that anyone in a position to control the content of the educational activity (planners and speakers/authors/discussants/moderators) has disclosed all relevant financial relationships with any commercial interest (see below for definitions).

Commercial Interest

The ACCME defines a “commercial interest” as any entity producing, marketing, re-selling, or distributing health care goods or services used on or consumed by patients. Providers of clinical services directly to patients are NOT included in this definition.

Financial Relationships

Relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.

Conflict of Interest

Circumstances create a conflict of interest when an individual has an opportunity to affect CME content about products or services of a commercial interest with which he/she has a financial relationship.

The ACCME also requires that ACS manage any reported conflict and eliminate the potential for bias during the educational activity. Any conflicts noted below have been managed to our satisfaction. The disclosure information is intended to identify any commercial relationships and allow learners to form their own judgments. However, if you perceive a bias during the educational activity, please report it on the evaluation.

Presenter and Disclosures

Beth Overmoyer, MD, FACP - Genentech, Eisai, Incyte: Clinical Trial Support, Consultant
Dana Farber Cancer Institute, Boston, MA

Beth Overmoyer, MD, FACP, is a national and international expert on inflammatory breast cancer. She is currently the director of the Inflammatory Breast Cancer Program at Dana Farber Cancer Institute, which is one of three dedicated programs in the United States focusing on the care of patients with inflammatory breast cancer. Dr. Overmoyer received her MD from Case Western Reserve School of Medicine followed by training in internal medicine and hematology and oncology at the Hospital of the University of Pennsylvania. She became the director of breast cancer research under the Case Comprehensive Cancer Center in Cleveland prior to joining Dana Farber. In addition to publishing extensively on inflammatory breast cancer, Dr. Overmoyer has been the principal investigator of several clinical trials designed specifically for inflammatory breast cancer and oversees the translational research that result from these studies.

Planning Committee Members and Disclosures

Asa Carter, MBA, CTR - Nothing to disclose
Ginny Mason, RN - Nothing to disclose
Beth Overmoyer, MD, FACP - Genentech, Eisai, Incyte: Clinical Trial Support, Consultant
Colette Salm-Schmid, MD, FACS  - Nothing to disclose
Andréa Scrementi - Nothing to disclose
Mary Lou Smith, JD, MBA - Nothing to disclose

Continuing Medical Education Credit Information


The American College of Surgeons is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA PRA Category 1 Credits™

The American College of Surgeons designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Of the AMA PRA Category 1 Credits™ listed above, a maximum of 1 credit meets the requirements for Self-Assessment.

American College of Surgeons and ACGME Logos


Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Completion
  • 1.00 Self Assessment Credit
Please login or register to take this course.

You may enroll in the online course at no charge. You will be asked to register for the course and provide information to complete the registration process. You will not be charged a participation fee.